GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Research & Development

CG Oncology (CG Oncology) Research & Development : $33.13 Mil (TTM As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. CG Oncology's Research & Development for the three months ended in Mar. 2024 was $17.21 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was $33.13 Mil.

CG Oncology Research & Development Historical Data

The historical data trend for CG Oncology's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Research & Development Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23
Research & Development
18.32 29.03 45.75

CG Oncology Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial 7.66 7.84 - 15.92 17.21

CG Oncology Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $33.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CG Oncology  (NAS:CGON) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

CG Oncology Research & Development Related Terms

Thank you for viewing the detailed overview of CG Oncology's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Research & Development
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024